BridgeBio Pharma BBIO 深 滬
等待開盤 05-13 09:30:00 美东时间
65.95
+1.270
+1.96%
華盛通- 最 高66.02
- 今 開64.94
- 成交量 241.00万股
- 最 低 64.235
- 昨 收 64.68
- 總市值 129.13亿
- 52周最高 84.94
- 市盈率 靜 --
- 換手率 1.23%
- 52周最低 31.77
- 委 比 -73.65%
- 總股本 1.96亿
- 歷史最高 84.94
- 量 比 0.72
- 振 幅 2.76%
- 歷史最低 4.98
- 每 手 1
- 風險率 13.89%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BridgeBio Oncology Q1 EPS $(526.11) Down From (54.230) YoY,
BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(526.11).This is a 870.15 percent decrease over losses of $(54.23) per share from the same period last year.
今天 05:54
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
BridgeBio falls despite new Attruby data
BridgeBio Pharma (BBIO) is down ~4% in Monday trading despite releasing phase 3 heart failure data for Attruby (acoramidis). Results from the ATTRibute-CM study found that the drug led to consistent a...
05-12 03:11
美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
BridgeBio Pharma Signals Atruvio‑Led Turnaround
Bridgebio Pharma (($BBIO)) has held its Q1 earnings call. Read on for the main ...
05-09 08:13
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma granted equity awards to 52 new employees, totaling 115,007 shares, with 25% vesting on May 16, 2027, and the remainder vesting quarterly over three years. The grants were made under Nasdaq Listing Rule 5635(c)(4) and the amended BridgeBio Pharma, Inc. Plan. The company focuses on developing medicines for genetic conditions using a decentralized model to accelerate innovation for underserved patient populations.
05-08 20:01
财报速睇 | BridgeBio Pharma 2026财年Q1营收1.95亿美元，同比增长66.8%；归母净利润亏损1.64亿美元，同比亏损缩窄2.0%
华盛资讯5月8日讯，BridgeBio Pharma公布2026财年Q1业绩，公司Q1营收1.95亿美元，同比增长66.8%，归母净利润亏损1.64亿美元，同比亏损缩窄2.0%。
05-08 10:38
财报速睇 | BridgeBio Pharma 2026财年Q1营收1.95亿美元，同比增长66.8%；归母净利润亏损1.64亿美元，同比亏损缩窄2.0%
华盛资讯5月8日讯，BridgeBio Pharma公布2026财年Q1业绩，公司Q1营收1.95亿美元，同比增长66.8%，归母净利润亏损1.64亿美元，同比亏损缩窄2.0%。
05-08 09:34
BridgeBio Pharma Announces $500 Million Stock Repurchase Program
BridgeBio Pharma ( ($BBIO) ) just unveiled an announcement. BridgeBio reported ...
05-08 05:51
BridgeBio Pharma's Acoramidis Receives Marketing Authorization From Brazil's Health Regulatory Agency To Treat Transthyretin Amyloidosis
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced the Brazilian Health Regulatory Agency (ANVISA) has granted
05-06 19:42
